Mouse Anti-LPCAT3 Recombinant Antibody (A919) (CBMAB-AP4338LY)

Inagaki, N. F., Nakanishi, H., Ohto, T., Shindou, H., & Shimizu, T. (2024). LPCAT3/LPLAT12 deficiency in the liver ameliorates acetaminophen‐induced acute liver injury. The FASEB Journal, 38(1), e23328.

Cui, J., Wang, Y., Tian, X., Miao, Y., Ma, L., Zhang, C., ... & Zhang, X. (2023). LPCAT3 is transcriptionally regulated by YAP/ZEB/EP300 and collaborates with ACSL4 and YAP to determine ferroptosis sensitivity. Antioxidants & redox signaling, 39(7-9), 491-511.

Hu, J., Deng, Y., Ding, T., Dong, J., Liang, Y., & Lou, B. (2023). Lpcat3 deficiency promotes palmitic acid-induced 3T3-L1 mature adipocyte inflammation through enhanced ROS generation: Lpcat3 deficiency promotes adipocyte inflammation. Acta Biochimica et Biophysica Sinica, 55(1), 117.

Lagrost, L., & Masson, D. (2022). The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease. Current Opinion in Lipidology, 33(3), 193-198.

Reed, A., Ichu, T. A., Milosevich, N., Melillo, B., Schafroth, M. A., Otsuka, Y., ... & Cravatt, B. F. (2022). LPCAT3 inhibitors remodel the polyunsaturated phospholipid content of human cells and protect from ferroptosis. ACS Chemical Biology, 17(6), 1607-1618.

Shao, G., Qian, Y., Lu, L., Liu, Y., Wu, T., Ji, G., & Xu, H. (2022). Research progress in the role and mechanism of LPCAT3 in metabolic related diseases and cancer. Journal of Cancer, 13(8), 2430.

Ding, Y., Cui, K., Han, S., Hao, T., Liu, Y., Lai, W., ... & Ai, Q. (2022). Lysophosphatidylcholine acyltransferase 3 (LPCAT3) mediates palmitate-induced inflammation in macrophages of large yellow croaker (Larimichthys crocea). Fish & Shellfish Immunology, 126, 12-20.

Ichu, T. A., Reed, A., Ogasawara, D., Ulanovskaya, O., Roberts, A., Aguirre, C. A., ... & Cravatt, B. F. (2020). ABHD12 and LPCAT3 interplay regulates a lyso-phosphatidylserine-C20: 4 phosphatidylserine lipid network implicated in neurological disease. Biochemistry, 59(19), 1793-1799.

Liu, N., Sun, Q., Xu, H., Yu, X., Chen, W., Wei, H., ... & Lu, W. (2020). Hyperuricemia induces lipid disturbances mediated by LPCAT3 upregulation in the liver. The FASEB Journal, 34(10), 13474-13493.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols